A randomized, double-blind, positive-controlled, 3-way cross-over human experimental pain study of a TRPV1 antagonist (V116517) in healthy volunteers and comparison with preclinical profile-Reference-Cited by-同舟云学术

A randomized, double-blind, positive-controlled, 3-way cross-over human experimental pain study of a TRPV1 antagonist (V116517) in healthy volunteers and comparison with preclinical profile

Published:2016-05-09 Issue:9 Volume:157 Page:2057-2067
ISSN:0304-3959
Container-title:Pain
language:en
Short-container-title:PAIN

Author:

Arendt-Nielsen Lars,Harris Steve,Whiteside Garth T.,Hummel Michele,Knappenberger Terri,O'Keefe Sarah,Kapil Ram,Kyle Don

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Anesthesiology and Pain Medicine,Clinical Neurology,Neurology

Reference53 articles.

1. Cytokine profile in human skin in response to experimental inflammation, noxious stimulation, and administration of a COX-inhibitor: a microdialysis study;Angst;PAIN,2008

2. Central sensitization in humans: assessment and pharmacology;Arendt-Nielsen;Handb Exp Pharmacol,2015

3. Optimizing the early phase development of new analgesics by human pain biomarkers;Arendt-Nielsen;Expert Rev Neurother,2011

4. Translational pain biomarkers in the early development of new neurotherapeutics for pain management;Arendt-Nielsen;Expert Rev Neurother,2014

5. Trial watch: phase II failures: 2008-2010;Arrowsmith;Nat Rev Drug Discov,2011

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current insights and therapeutic strategies for targeting TRPV1 in neuropathic pain management;Life Sciences;2024-10

2. Topically applied novel TRPV1 receptor antagonist, ACD440 Gel, reduces evoked pain in healthy volunteers, a randomized, double‐blind, placebo‐controlled, crossover study;European Journal of Pain;2024-06-12

3. Pathology of pain and its implications for therapeutic interventions;Signal Transduction and Targeted Therapy;2024-06-08

4. Biology of Bone Cancer Pain;Metastatic Bone Disease;2024

5. TRPV1 antagonists: Future drug discovery directions;TRP Channels as Therapeutic Targets;2024